135P Camrelizumab plus chemotherapy as first-line therapy for NSCLC: A pooled analysis of two randomized phase III trials with extended follow-up. (December 2022) - Zhou, C.; Chen, G.; Huang, Y.; Chen, J.; Cheng, Y.; Wang, Q.; Pan, Y.; Zhou, J.; Shi, J.; Xu, X.; Lin, L.; Zhang, W.; et al.